Previous close | 1.6000 |
Open | 5.6442 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 1.6000 - 1.6000 |
52-week range | 0.2985 - 1.6000 |
Volume | |
Avg. volume | 3,158 |
Market cap | 39.496M |
Beta (5Y monthly) | 1.61 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.8300 |
Earnings date | 29 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
LYON, France, July 15, 2024--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today publishes its cash position, provides an update on its financial situation for the second quarter and first half of 2024, ending June 30, 2024, reviews its activities on June 30, 2024 and an
LYON, France, May 16, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today reported its revenue for the quarter ended March 31, 2024 and provided a business update.
LYON, France, April 29, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today reported its cash position, provided a financial and business update for the first quarter ended March 31, 2024, and announced the postponement of its 2023 full-year results re